

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

- 1-6. (Cancelled)
7. (Currently Amended) A recombinant vector containing the nucleic acid molecule of claim 4 16.
8. (Original) The recombinant vector of claim 7 wherein the nucleic acid molecule is operatively linked to regulatory elements allowing transcription and synthesis of a translatable RNA in prokaryotic and/or eukaryotic host cells.
9. (Currently Amended) A recombinant host cell which contains a nucleic acid molecule according to claim 4 16.
10. (Original) The recombinant host cell of claim 9, which is a mammalian cell, a bacterial cell, an insect cell or a yeast cell.
11. (Cancelled) A pharmaceutical composition comprising a compound which is capable of regulating the expression of the MCP-1 gene by directly or indirectly interacting with the nucleic acid sequence (b) of any one of claims 1 to 6 or the recombinant vector of claim 7 or 8.

12. (Cancelled) The pharmaceutical composition of claim 11, wherein the compound is a protein capable of interacting with a transcription factor, in particular AP-1, or a nucleic acid molecule encoding said protein.

13. (Cancelled) The pharmaceutical composition of claim 12, wherein the compound is *jun*, *fra-1*, *ATF-2*, *jab-1*, *fra-2* or a mixture thereof.

14. (Cancelled) Use of the compounds as defined in any one of claims 11 to 13 for the preparation of a medicament for the treatment of atherosclerosis or cancer.

15. (Cancelled) Use according to claim 14, wherein the cancer is a cervical carcinoma.

16. (Currently Amended) An isolated nucleic acid molecule comprising consisting essentially of

(a) a nucleic acid sequence encoding the monocyte-chemoattractant-protein-1 (MCP-1), the protein encoded by the nucleic acid sequence of SEQ ID NO:13 ~~EMBL Accession No. Y18933~~ or an allelic variant thereof or a sequence which is degenerate as a result of the genetic code to SEQ ID NO:13 or a nucleic acid sequence which hybridize to ~~said MCP-1~~ the nucleic acid nucleotide sequence of SEQ ID NO:13 under stringent conditions ~~or fragments, derivatives or allelic variants of said sequence which encode a protein having the biological activity of the monocyte chemoattractant protein 1 (MCP-1) and an amino acid sequence identity of at least 80% to the amino acid sequence encoded by the EMBL clone (Y18933); and~~

(b) at least one hypersensitive region, wherein said hypersensitive region is a 5'-DHSR selected from the group consisting of SEQ. ID. NOs: 4, 5, 6 or a 3'-DHSR selected from the group consisting of SEQ. ID NOs: 1, 2, 3, 8 or the nucleic acid molecule TGATCA .

17. (Cancelled)

18. (Original) The nucleic acid molecule of claim 16, wherein the hypersensitivity sequences (b) contain a binding site for a transcription factor.

19. (Original) The nucleic acid molecule of claim 18, wherein the transcription factor is AP-1, SP1, NF-IL6 or NF-kappa B.

20. (Cancelled)

21. (New) The isolated nucleic acid molecule of claim 16, wherein the nucleic acid molecule of (a) has the sequence of SEQ ID NO:13.